Gsk Pharma
Mar 13, 2012 at 15:47 | Source: Moneycontrol.com
Mar 02, 2012 at 12:46 | Source: Moneycontrol.com
Feb 23, 2012 at 14:37 | Source: Moneycontrol.com
Feb 22, 2012 at 16:16 | Source: Moneycontrol.com
Feb 20, 2012 at 17:13 | Source: Moneycontrol.com
News across the web »
May 22, 2012 at 22:11 | Source: The Hindu BusinessLine
May 22, 2012 at 10:02 | Source: DNA India
May 09, 2012 at 07:52 | Source: Economic Times
May 09, 2012 at 02:42 | Source: Economic Times
Apr 08, 2012 at 02:22 | Source: The Hindu BusinessLine
Interact & exchange stock tips & market info »
Related News »
But GSK's deep interests in key HGS assets such as Benlysta could discourage outside bidders from entering the fray. However, other biotech companies enter collaborations with pharma giants such as GSK in hopes of being acquired. GSK scooped up ...
May 25, 2012 at 14:52 | Source: FierceBiotech
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, and GlaxoSmithKline LLC, the US subsidiary of GlaxoSmithKline plc (GSK), have entered into an ...
May 22, 2012 at 10:16 | Source: pharmabiz.com
GSK will promote Testim using a sizeable established field ... in the U.S. In a separate press release, Auxilium Pharma said it is raising its full year 2012 revenue guidance to a range of $293 million to $315 million from prior forecast of ...
May 20, 2012 at 23:55 | Source: NASDAQ
recently entered into a co-promotion agreement with GlaxoSmithKline plc‘s (GSK) U.S. subsidiary, GlaxoSmithKline LLC. The companies signed an agreement for the co-promotion of Auxilium Pharma’s Testim (1% testosterone), which is approved for ...
May 22, 2012 at 13:22 | Source: Yahoo Finance
Pharmaceutical giant GSK originally offered US$13 per share for HGS, which it partners with on lupus drug, Benlysta. The autoimmune disease drug is seen as a key motivation behind GSK’s takeover plan. The American biotech rejected the original US$2.6 ...
May 23, 2012 at 16:56 | Source: proactiveinvestors.com
In announcing the acquisition, in which GSK will add all the outstanding shares the pharma giant didn't already own, the R&D division had high praise for technology capable of spying drug interactions with target proteins in what it called a ...
May 14, 2012 at 23:55 | Source: FierceBiotech
British pharma giant GlaxoSmithKline ( GSK) recently announced that it has completed the acquisition of 10,000,000 shares of biopharmaceutical company Theravance Inc. ( THRX). Shares were acquired for approximately $21.2887 per share.
May 17, 2012 at 17:39 | Source: NASDAQ
GSK has been invited to participate in that process ... according to consensus forecasts compiled by Thomson Reuters Pharma. Investors are likely to be emboldened in thinking they can get more for their Human Genome shares in the light of recent ...
May 23, 2012 at 18:51 | Source: Globe and Mail
GSK will promote Testim using a sizeable established field sales ... in 46 countries in Eurasia; Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial ...
May 21, 2012 at 12:48 | Source: Phramalive.com
For GSK, HGS’ biologic pipeline will broaden its footprint in this segment of drug development. GSK would be following its big pharma brethren like Merck & Co., Pfizer, Roche, and Sanofi. All have doled out major mullah for biotech companies ...
May 10, 2012 at 13:30 | Source: Genetic Engineering News